AI Article Synopsis
- Primary biliary cholangitis and primary sclerosing cholangitis are uncommon liver diseases that primarily impact the bile ducts, and there is still much to learn about their causes.
- Due to limited understanding, treatment options have historically been scarce, but new therapies are emerging that could improve patient care.
- This review focuses on summarizing research into new potential treatments for these conditions and explores how these advancements might transform existing approaches to treatment.
Article Abstract
Primary biliary cholangitis and primary sclerosing cholangitis are rare diseases affecting the bile ducts and the liver. The limited knowledge of their pathogenesis leads to limited therapeutic options. Nevertheless, the landscape of novel therapies for these cholangiopathies is now rapidly changing, providing new treatment opportunities for patients and clinicians involved in their care. The aim of this review is to summarize the evidence of novel molecules under investigation for primary biliary cholangitis and primary sclerosing cholangitis and to discuss how they can potentially change current treatment paradigms.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.aohep.2019.09.009 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!